NCT04554940
Source recordAI-normalized
A Randomized, Controlled, Open-label Clinical Trial With an Open-label Extension to Investigate the Safety of Vosoritide in Infants and Young Children With Achondroplasia at Risk of Requiring Cervicomedullary Decompression Surgery
Study 111-209 is a Phase 2 randomized, open-label clinical trial of BMN 111 in infants and young children with a diagnosis of Achondroplasia at a heightened risk of requiring cervicomedullary decompression surgery
AI analysis
Indication: Achondroplasia
Modality: protein therapy
Target: vosoritide
Sponsor: BioMarin Pharmaceutical
Source URL: ClinicalTrials.gov
Source updated: Mar 13, 2026
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: vosoritide
View original source fields
Condition raw: Achondroplasia
Condition normalized: Achondroplasia
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: vosoritide
Target normalized: vosoritide